Article · 9 Nov 2026
Research articlePublished 2016
Beneficiary Effect of Combination Therapy of Metformin and Pitavastatin Drug on Alloxan Induced Diabetic Rats Comparing to Single Drug Therapy
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: The present study was designed to investigate the antihyperglycemic, antidyslipidemic effects and hepatoprotectivity of the fixed dose combination of metformin [850 mg/70 kg body weight (BW)] and pitavastatin [2 mg/70 kg (BW)] on alloxan induced (120 mg/kg BW) diabetic rats. Methods: A well-established method was implemented to evaluate the effects of combination drug therapy of metformin and pitavastatin on alloxan induced diabetic rats. This study has been designed to evaluate the effects of metformin, pitavastatin and combination on blood glucose level, triglyceride (TG) level, LDL cholesterol level, total cholesterol level, liver dysfunction indices (ALT), liver dysfunction indices (AST), effect of drugs and their combination on left ventricle, survival rate of diabetic treated rats, compare weight of different groups and justify among them. The statistical method applied in each analysis was described in each figure. Results were considered to be significant when p values were less than 0.05 (p<0.05). Results: In alloxan induced diabetic rats, combination therapy induced a significant decrease in blood glucose level from 15.5 ± 0.01 to 6 ± 0.03 mmol/L two hours after last dose administration, after daily treatment for two weeks. In case of dyslipidemic effect, combination therapy reduced total cholesterol (33%), triglyceride (36%) and LDL-cholesterol (34%) levels significantly and increased HDL-cholesterol level (67%) in comparison with their respective diabetic control groups. It was also observed that combination therapy decreased LV hypertrophy (47%) in comparison with diabetic control group effectively. It was also observed that combination therapy decreased ALT (46%) and AST (35%) in comparison with diabetic control group effectively. Conclusion: In conclusion pitavastatin potentiates the antihyperglycemic, antidyslipidemic and hepatoprotectivity of metformin on alloxan induced diabetic rats. The results of the present study suggest that, combination of metformin and pitavastatin might be efficacious in patients with diabetic dyslipidemia and increased hepatoprotectivity.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical & Experimental Pharmacology.
Article · 23 Feb 2026
A Thorough Overview of Polycystic Ovary Syndrome (PCOS) in Female Rats
Article · 19 Dec 2025
Theoretical Pharmacology: Understanding Drug Action Through Models and Principles
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical & Experimental Pharmacology
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Tanjir Islam Md”
- BylineArticles whose byline prints “Nasrin S”
- BylineArticles whose byline prints “Rashid M”
- BylineArticles whose byline prints “Sultana T”
- BylineArticles whose byline prints “Hassan Kawsar Md”
- BylineArticles whose byline prints “Helal Uddin Sumon Md”
- BylineArticles whose byline prints “Didaruzzaman Sohel Md”
